PLOD1 and nonpapillary renal cell carcinoma: The robust correlation between PLOD expression levels and therapeutic response profiles positions the PLOD gene family as promising biomarkers for predicting drug sensitivity and guiding personalized treatment strategies in ccRCC patients.